{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T20:04:14Z","timestamp":1779393854687,"version":"3.53.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hospitalized medically ill patients with cancer are at increased risk of both venous thromboembolism and bleeding. The safety and efficacy of extended thromboprophylaxis in patients with cancer are unclear. We conducted a systematic review and meta-analysis of the literature using of MEDLINE, EMBASE, and the Cochrane CENTRAL databases to identify cancer subgroups enrolled in randomized controlled trials evaluating extended thromboprophylaxis following hospitalization. The primary outcomes were symptomatic and incidental venous thromboembolic events and hemorrhage (major hemorrhage and clinically relevant nonmajor bleeding). Four randomized controlled trials reported the outcomes of extended thromboprophylaxis in 3655 medically ill patients with active or history of cancer. The rates of venous thromboembolic events were similar between the extended-duration and standard-duration groups (odds ratio [OR], 0.85; 95% confidence interval [CI], 0.61-1.18; I2 = 0%). However, major and clinically relevant nonmajor bleeding occurred significantly more frequently in the extended-duration thromboprophylaxis group (OR, 2.10; 95% CI, 1.33-3.35; I2 = 8%). Extended thromboprophylaxis in hospitalized medically ill patients with cancer was not associated with a reduced rate of venous thromboembolic events but was associated with increased risk of hemorrhage. This study protocol was registered on PROSPERO as #CRD42020209333.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020004118","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T09:41:13Z","timestamp":1618652473000},"page":"2055-2062","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis"],"prefix":"10.1182","volume":"5","author":[{"given":"Soravis","family":"Osataphan","sequence":"first","affiliation":[{"name":"Department of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8426-3398","authenticated-orcid":false,"given":"Rushad","family":"Patell","sequence":"additional","affiliation":[{"name":"Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0443-1751","authenticated-orcid":false,"given":"Thita","family":"Chiasakul","sequence":"additional","affiliation":[{"name":"Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;"},{"name":"Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-6893","authenticated-orcid":false,"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[{"name":"Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"issue":"2","key":"2021041615324754100_B1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood-2016-12-758995","article-title":"Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US","volume":"130","author":"Heit","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2021041615324754100_B2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jamainternmed.2014.3384","article-title":"Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism: a cohort study","volume":"174","author":"Flanders","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2021041615324754100_B3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.thromres.2019.10.027","article-title":"Extended vs. standard-duration thromboprophylaxis in acutely ill medical patients: a systematic review and meta-analysis","volume":"184","author":"Chiasakul","year":"2019","journal-title":"Thromb Res"},{"issue":"5","key":"2021041615324754100_B4","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/blood-2016-10-747931","article-title":"Extended thromboprophylaxis with direct oral anticoagulants for medical patients: a systematic review and meta-analysis","volume":"129","author":"Tao","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2021041615324754100_B5","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"2021041615324754100_B6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2021041615324754100_B7","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/archinte.168.12.1261","article-title":"Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis","volume":"168","author":"Akl","year":"2008","journal-title":"Arch Intern Med"},{"issue":"12","key":"2021041615324754100_B8","first-page":"CD008500","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Di Nisio","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2021041615324754100_B9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.amjmed.2005.06.058","article-title":"Incidence of venous thromboembolism in patients hospitalized with cancer","volume":"119","author":"Stein","year":"2006","journal-title":"Am J Med"},{"issue":"10","key":"2021041615324754100_B10","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2021041615324754100_B11","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"23","key":"2021041615324754100_B12","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"2021041615324754100_B13","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMoa1805090","article-title":"Rivaroxaban for thromboprophylaxis after hospitalization for medical illness","volume":"379","author":"Spyropoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"2021041615324754100_B14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2021041615324754100_B15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/0003-4819-153-1-201007060-00004","article-title":"Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial","volume":"153","author":"Hull","year":"2010","journal-title":"Ann Intern Med"},{"issue":"6","key":"2021041615324754100_B16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2021041615324754100_B17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s11239-019-01943-5","article-title":"Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial","volume":"49","author":"Ageno","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"8","key":"2021041615324754100_B18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"2021041615324754100_B19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"2021041615324754100_B20","first-page":"CD004318","article-title":"Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery","volume":"11","author":"Felder","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2021041615324754100_B21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.amjmed.2011.07.031","article-title":"Venous thromboembolism prophylaxis for medical service-mostly cancer-patients at hospital discharge","volume":"124","author":"Fanikos","year":"2011","journal-title":"Am J Med"},{"key":"2021041615324754100_B22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2018.07.010","article-title":"Bleeding and venous thromboembolic events in patients with active cancer hospitalized for an acute medical illness","volume":"169","author":"Di Nisio","year":"2018","journal-title":"Thromb Res"},{"key":"2021041615324754100_B23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.thromres.2017.08.005","article-title":"Identifying predictors for bleeding in hospitalized cancer patients: a cohort study","volume":"158","author":"Patell","year":"2017","journal-title":"Thromb Res"},{"issue":"7","key":"2021041615324754100_B24","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1182\/bloodadvances.2019000840","article-title":"DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines","volume":"4","author":"Neumann","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2021041615324754100_B25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjmed.2013.09.015","article-title":"Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer","volume":"127","author":"Carrier","year":"2014","journal-title":"Am J Med"},{"issue":"10","key":"2021041615324754100_B26","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/bloodadvances.2020001804","article-title":"Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial","volume":"4","author":"Zwicker","year":"2020","journal-title":"Blood Adv"},{"issue":"31","key":"2021041615324754100_B27","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2018.78.4595","article-title":"Long-term risk of venous thromboembolism in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"36","author":"Madenci","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10203","key":"2021041615324754100_B28","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"2021041615324754100_B29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/ajh.24700","article-title":"Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool","volume":"92","author":"Patell","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"2021041615324754100_B30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"3","key":"2021041615324754100_B31","doi-asserted-by":"crossref","first-page":"e0213940","DOI":"10.1371\/journal.pone.0213940","article-title":"Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: a systematic review and network meta-analysis","volume":"14","author":"Rossel","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"2021041615324754100_B32","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.3802\/jgo.2020.31.e10","article-title":"Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers","volume":"31","author":"Lee","year":"2020","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"2021041615324754100_B33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2021041615324754100_B34","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/8\/2055\/1805251\/advancesadv2020004118.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/8\/2055\/1805251\/advancesadv2020004118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T09:41:38Z","timestamp":1618652498000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/8\/2055\/475732\/Extended-thromboprophylaxis-for-medically-ill"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,4,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020004118","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]}}}